Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

• 3 Momentum Stocks Soaring Into 2025 and Beyond

A number of other equities analysts have also recently weighed in on MNPR. Zacks Research raised shares of Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Monopar Therapeutics in a research note on Wednesday, July 15th. BTIG Research raised their price target on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. HC Wainwright lifted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, July 22nd. Finally, Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $112.08.

Get Our Latest Research Report on MNPR

Monopar Therapeutics Trading Down 0.8%

• MarketBeat Week in Review – 10/21- 10/25

Shares of MNPR opened at $119.21 on Friday. The firm has a market cap of $798.71 million, a P/E ratio of -62.74 and a beta of 1.47. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $124.82. The company's 50-day moving average price is $90.83 and its 200 day moving average price is $70.05.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. Equities research analysts forecast that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Institutional Inflows and Outflows

• Monopar Therapeutics Skyrockets 400% on Licensing Deal

A number of institutional investors have recently made changes to their positions in MNPR. Janus Henderson Group PLC lifted its holdings in Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company's stock worth $85,908,000 after buying an additional 30,042 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company's stock worth $43,569,000 after acquiring an additional 156,000 shares in the last quarter. Siren L.L.C. grew its stake in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock worth $14,800,000 after acquiring an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock worth $14,480,000 after acquiring an additional 30,370 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Monopar Therapeutics during the third quarter worth $18,904,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

Further Reading

• Five stocks we like better than Monopar Therapeutics
• Datadog’s Drop Says More About Expectations Than Earnings
• D-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-Off
• Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
• Solventum Nears Inflection Point As It Begins to Unlock Value

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Monopar Therapeutics Right Now?

Before you consider Monopar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.

While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here